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Background: Increasing scientific evidence suggests that exposure to phthalates during pregnancy may be associated
with an elevated risk of adverse reproductive outcomes such as preterm birth. Maternal endocrine disruption across
pregnancy may be one pathway mediating some of these relationships. We investigated whether urinary phthalate
metabolites were associated with maternal serum thyroid (free thyroxine [FT4], free triiodothyronine [FT3], and
thyroid-stimulating hormone [TSH]), and sex (estradiol, progesterone, and sex hormone-binding globulin [SHBG])
hormone levels at multiple time points during pregnancy.
Methods: Preliminary data (n = 106) were obtained from an ongoing prospective birth cohort in Northern Puerto
Rico. We collected urine and serum sample at the first and third study visits that occurred at 18 +/− 2 and 26 +/−
2 weeks of gestation, respectively. To explore the longitudinal relationships between urinary phthalate metabolites and
serum thyroid and sex hormone concentrations, we used linear mixed models (LMMs) adjusted for prepregnancy body
mass index (BMI) and maternal age. An interaction term was added to each LMM to test whether the effect of urinary
phthalate metabolites on serum thyroid and sex hormone levels varied by study visit. In cross-sectional analyses, we
stratified BMI- and age-adjusted linear regression models by study visit.
Results: In adjusted LMMs, we observed significant inverse associations between mono-3-carboxypropyl phthalate
(MCPP) and FT3 and between mono-ethyl phthalate (MEP) and progesterone. In cross-sectional analyses by study visit,
we detected stronger and statistically significant inverse associations at the third study visit between FT3 and MCPP as
well as mono-carboxyisooctyl phthalate (MCOP); also at the third study visit, significant inverse associations were
observed between FT4 and metabolites of di-(2-ethylhexyl) phthalate (DEHP). The inverse association between
MEP and progesterone was consistent across study visits.
Conclusions: In this group of pregnant women, urinary phthalate metabolites may be associated with altered
maternal serum thyroid and sex hormone levels, and the magnitude of these effects may depend on the timing
of exposure during gestation.
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Phthalate diesters are commonly used as plasticizers in
industrial applications [1]. Additionally, many household
and consumer products, including flooring and wall cover-
ings, food packaging, and cosmetics such as lotions and
fragrances, contain phthalates [2-4]. Due to their ubiqui-
tous use, human exposure to phthalates is widespread [5].
Because phthalates are not chemically bound to the plas-
tics and other products that contain them, they can easily
leach into household dust, food and water sources, and
ambient air [1,6,7]. Consequently, human exposure to
phthalates can occur through ingestion, inhalation, or
dermal absorption [1,3].
Growing evidence suggests that urinary concentrations
of phthalate metabolites during pregnancy are associated
with adverse reproductive outcomes including preterm
birth and pregnancy loss [8,9]. Hormonal production and
regulation are critical for pregnancy maintenance and fetal
growth and neurodevelopment; maternal endocrine dis-
ruption during pregnancy may be one pathway mediating
some of these relationships [10-13].
Limited human health studies have examined the poten-
tial thyroid-altering effects of phthalates. In a cross-sectional
study of men recruited from a U.S. fertility clinic, the urinary
concentration of mono-(2-ethylhexyl) phthalate (MEHP), a
metabolite of di-(2-ethylhexyl) phthalate (DEHP), was in-
versely associated with free thyroxine (3, 3’, 5, 5’-tetraiodo-
L-thyronine, FT4) and total triiodothyronine (3, 3’,
5-triiodo-L-thyronine, T3) [14]. Urinary concentrations of
DEHP metabolites were also inversely associated with total
T3 and total and free T4, and positively associated with
thyroid-stimulating hormone (thyrotropin, TSH) in a rep-
resentative sample of U.S. adults (non-pregnant women
and men) participating in the National Health and Nutri-
tional Examination Survey (NHANES) [15]. Similar inverse
relationships between urinary DEHP metabolites and total
and free T3 (FT3) were reported in a cross-sectional study
of Danish children [16]. While pervasive exposure to
phthalates has been documented among pregnant women
worldwide [17-22], human health studies investigating the
effects of phthalate exposure during pregnancy on mater-
nal thyroid function are scarce. Huang and colleagues [23]
reported an inverse association between urinary concen-
trations of monobutyl phthalate (MBP), the metabolite of
dibutyl phthalate (DBP), and both free and total T4 in the
second trimester of Taiwanese pregnant women.
Animal and in vitro studies have also shown that phtha-
lates can interfere with sex hormone concentrations,
signaling, and/or function [24,25], which may profoundly
affect implantation, fetal development, and parturition
[10,26]. However, human data pertaining to the relation-
ships between phthalates and sex hormones are limited.
In men recruited through a U.S. fertility clinic, urinary
MEHP was inversely associated with serum estradiol levels[27]. A positive association between urinary MEHP and
sex hormone-binding globulin (SHBG) was also reported
in separate cohort of fertile U.S. men [28]. In a recent
study conducted among pregnant women in the U.S.,
an inverse association was found between urinary DEHP
metabolite concentrations and serum testosterone con-
centrations, while no statistically significant relationship
was observed for estradiol [29]. Additionally, Hart and
coauthors [30] reported significantly inverse correlations
between serum MEHP and SHBG concentrations at both
18 weeks and 36 weeks of gestation among pregnant
women in Australia.
We are aware of no published investigations that longi-
tudinally evaluate the potential thyroid-disrupting effects
of environmental phthalate exposure among pregnant
women. Furthermore, whether alterations in thyroid
and sex hormone levels vary by time point of exposure
during gestation remains largely undetermined and may
have important influences on downstream hormone-
mediated reproductive outcomes. In this preliminary ana-
lysis, we investigated the relationship between urinary
phthalate metabolites and maternal serum thyroid (FT3,
FT4, and TSH) and sex (estradiol, progesterone, and
SHBG) hormone levels measured in samples collected
at two time points in pregnancy from women participating
in a prospective birth cohort in Puerto Rico.
Methods
Study population
The Puerto Rico Testsite for Exploring Contamination
Threats (PROTECT) project is an ongoing prospective
birth cohort in the Northern Karst Region of Puerto Rico
designed to investigate the relationship between phthalates
and other environmental contaminants and adverse preg-
nancy outcomes such as preterm birth. A previous study
within this project reported greater concentrations of
some urinary phthalate metabolites measured in Puerto
Rican participants compared to women of reproductive
age in the contiguous U.S. [31]. The current analysis in-
cluded data collected from the first 106 pregnant women
participating in the PROTECT project with urinary
phthalate metabolites and serum thyroid and sex hor-
mones measures completed as of November 2012. Study
participants, aged 18 to 40 years, were recruited around
14 ± 2 weeks gestation from 7 prenatal clinics and hospi-
tals throughout Northern Puerto Rico from 2010 to 2012.
Participant recruitment and eligibility criteria as well as
sample collection and processing are described in detail
elsewhere [31]. Demographic information was obtained
from questionnaires administered at the initial study visit.
Spot urine samples were collected from each participant
at three separate study visits (visit 1: 18 ± 2 weeks, visit 2:
22 ± 2 weeks, visit 3: 26 ± 2 weeks of gestation). Only urine
samples from visits 1 and 3 were utilized in the present
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2. All participants in the present analysis provided urine
and serum samples for at least one visit (visits 1 and/or 3).
Upon collection and processing (e.g., aliquoting, centrifu-
gation, and separation of blood into plasma and serum
components), all urine and blood samples were frozen
at −80°C until shipped overnight on dry ice to the analyt-
ical laboratories where samples were again stored at −80°C
until analysis.
The study protocols were approved by the ethics and
research committees of the participating institutions. The
involvement of the Centers for Disease Control and Pre-
vention (CDC) laboratory was determined not to consti-
tute engagement in human subjects research. The study
was described in detail to all participating women and all
study participants gave informed consent.
Measurement of phthalate metabolites
Available urine samples (N = 196 samples, N = 106 partici-
pants) were analyzed by the Centers for Disease Control
and Prevention (CDC) laboratories, using protocols devel-
oped for NHANES, to measure urinary concentrations
(free plus glucuronidated) of 11 phthalate metabolites:
MEHP, MBP, mono-2-ethyl-5-hydroxyhexyl phthalate
(MEHHP), mono-2-ethyl-5-oxohexyl phthalate (MEOHP),
mono-2-ethyl-5-carboxypentyl phthalate (MECPP), mono-
3-carboxypropyl phthalate (MCPP), mono-carboxyisooctyl
phthalate (MCOP), mono-carboxyisononyl phthalate
(MCNP), mono-benzyl phthalate (MBzP), mono-iso-butyl
phthalate (MiBP), and mono-ethyl phthalate (MEP). The
analytical method involved enzymatic deconjugation of
the metabolites from their glucuronidated form, solid-
phase extraction, separation by high-performance liquid
chromatography, and detection by isotope-dilution tan-
dem mass spectrometry [32]. The limits of detection
(LOD) were in the low nanogram per milliliter range
[31]. Concentrations below the LOD were assigned a
value of LOD divided by the square root of 2 [33]. To
account for urine dilution, urinary specific gravity (SG)
was measured using a digital handheld refractometer
(Atago Co., Ltd., Tokyo, Japan). For descriptive analyses,
metabolite concentrations were standardized using the fol-
lowing formula: PSG = P[(1.019 − 1)/(SG − 1)], where PSG is
the specific gravity-adjusted phthalate metabolite concen-
tration (ng/mL), P is the observed phthalate metabolite
concentration, 1.019 was the specific gravity population
median, and SG is the specific gravity of the urine sample.
Measurement of thyroid hormones
For 106 subjects, serum samples from visits 1 (N = 106)
and 3 (N = 89) were available for measurement of FT3,
FT4, and TSH at the Bioanalytical Core Laboratory of
Georgetown University (Washington, DC). Limitations in
sample volume contributed to differences in the numberof samples per study visit available for analysis. Following
an ultrafiltration step to separate the free hormones, FT3
and FT4 were measured using isotope dilution liquid
chromatography tandem mass spectrometry per the
methods described in detail previously [34-37]. TSH
concentrations were measured using a solid-phase immu-
nochemiluminometric assay (DPC Immulite, Diagnostic
Products Corporation) according to the manufacturer’s
instructions.
Measurement of sex hormones
For 104 subjects, serum samples were analyzed for estra-
diol (visit 1: N = 103 samples; visit 3: N = 86 samples)
and progesterone (visit 1: N = 104; visit 3: N = 89) using
a chemiluminescence immunoassay (DPC Immulite, Diag-
nostic Products Corporation). Serum levels of SHBG from
samples collected from 99 subjects (visit 1: N = 88; visit 3:
N = 69) were determined using the same procedures. Simi-
lar to the thyroid hormone analyses, limitations in sample
volume contributed to differences in available samples
for each sex hormone/study visit. These analyses were
also performed by the Bioanalytical Core Laboratory at
Georgetown University (Washington, DC).
Statistical analysis
Serum concentrations of FT4, FT3, estradiol, and SHBG
closely approximated normality and were untransformed
in statistical analyses. TSH, progesterone, and urinary
phthalate metabolite concentrations were positively skewed
and were logarithmically transformed prior to analyses.
Because MEHP, MEOHP, MEHHP, and MECPP share a
single parent compound, the sum of concentrations of
the DEHP metabolites (ΣDEHP) was calculated from the
molar sum (nmol/mL) of these four metabolites and log-
transformed in statistical analyses. Means and standard
deviations as well as selected percentiles were used to
examine the distributions of the urinary phthalate metabo-
lites, thyroid hormones, and sex hormones. Geometric
means and standard deviations were calculated for non-
normally distributed variables.
Pearson correlations were calculated to assess the rela-
tionships between continuous variables. To test the dif-
ferences in the mean concentrations of sex and thyroid
hormones by visit, we used linear mixed models (LMMs)
with serum hormones levels regressed on study visit and
included a random intercept for subject ID to account
for intra-individual correlation of repeated measurements
over time. Urinary phthalate metabolites and sex and
thyroid hormones were tested for associations with demo-
graphic variables to examine potential confounding. We
used LMMs with one phthalate metabolite concentra-
tion measure (as exposure) and one outcome per model
to explore the longitudinal relationships between urin-
ary phthalate metabolites and sex and thyroid hormone
Table 1 Sample characteristics of 106 pregnant women
participating in PROTECT project (2010–2012)
Variable Mean ± SD or n (%)
Maternal age at enrollment (years) 27.1 ± 4.8
Maternal education
Missing 3 (2.8)
<High school 12 (11.3)
High school/equivalent 7 (6.6)
College 84 (79.2)
Annual household income (US$)
Missing 17 (16.0)
$20,000 45 (42.4)







Prepregnancy BMI (kg m−2)
Missing 4 (3.8)
≤25 59 (55.7)










PROTECT, Puerto Rico Testsite for Exploring Contamination Threats, SD,
standard deviation, BMI, body mass index.
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specific gravity and study visit. Full models additionally
included maternal prepregnancy body mass index (BMI)
and age, both measured at the initial study visit. BMI
was modeled as a categorical variable (≤25 kg/m2, >25
and ≤30 kg/m2, >30 kg/m2) and age was modeled as a
continuous variable. BMI and age were included as co-
variates because of their potential influence on urinary
phthalate metabolite concentrations [38] and sex and
thyroid hormone levels [39-41]. A likelihood ratio test
for fixed effects was used to identify additional potential
covariates in full models. An interaction term was added
to each full LMM to test whether the effect of urinary
phthalate metabolites on thyroid and sex hormone serum
levels varied by study visit.
In a secondary analysis, we used linear regression models
with one phthalate metabolite concentration and one out-
come per model to investigate the cross-sectional relation-
ships between urinary phthalate metabolites and sex and
thyroid hormone serum concentrations at each study visit
(visits 1 and 3). These models were also adjusted for mater-
nal BMI, age, and urinary specific gravity. To enhance in-
terpretability, all regression coefficients and associated 95%
confidence intervals (CIs) generated from the LMMs and
linear regression models were expressed as the percent
change in hormone serum levels for an interquartile range
(IQR) increase in urinary phthalate metabolite concentra-
tions. Associations were considered statistically significant
at the 5% level and marginally significant at the 10% level.
All statistical analyses were conducted using SAS version
9.2 (SAS Institute Inc., Cary, NC).
Results
Table 1 shows the distribution of sociodemographic
characteristics of the 106 pregnant women included in
the present analysis. The study participants were generally
highly educated (79.2% had at least a college education),
and did not smoke during pregnancy (94.3%). Approxi-
mately half (55.7%) of the women had a prepregnancy
BMI ≤25 kg/m2. No statistically significant differences
were observed between the demographic characteristics
of study participants with measurable thyroid and sex
hormone concentrations at visit 1 vs. those with meas-
urable thyroid and sex hormone concentrations at visit
3 (chi-square test p-values > 0.05). Based on the eligibil-
ity criteria, no participants used oral contraceptives
within three months prior to pregnancy or underwent
in vitro fertilization as a method of assisted reproduct-
ive technology, and all participants were free of known
medical or obstetric complications.
The distributions of the 11 urinary phthalate metabolite
concentrations across pregnancy have been previously in-
vestigated in this cohort [31]. Greater than 90% of the mea-
sured concentrations of all 11 urinary phthalate metaboliteswere detectable [31]. Concentrations for a majority of the
metabolites measured were greater in the Puerto Rican par-
ticipants when compared to women of reproductive age in
the contiguous U.S. [31]. For example, the geometric mean
concentration of urinary MEHP (unadjusted for urinary
dilution) was more than twice as high in the Puerto Rican
cohort than the corresponding concentration found in
women of reproductive age participating in the 2009–
2010 NHANES study (3.3 vs. 1.6 ng/mL, respectively)
[31]. Spearman correlations between the majority of urin-
ary metabolites were modest (R = 0.23-0.45), while strong
correlations were observed between all urinary metabo-
lites of DEHP (MEHP, MEHHP, MEOHP, and MECPP;
R > 0.83) [31]. With the exception of MCOP, no statistically
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mean concentrations between study visits for any of the
other urinary phthalate metabolites (Additional file 1:
Table S1).
The distributions of the thyroid and sex hormones are
presented in Table 2. All of the measured concentrations
of the hormones were detectable. We found a signifi-
cantly positive Pearson correlation between estradiol and
progesterone (R = 0.66, p < 0.001). Weak but significant
positive correlations were observed between FT4 and
FT3 (R = 0.17, p = 0.02), and between SHBG and both
progesterone (R = 0.23, p = 0.004) and estradiol (R = 0.29,
p = 0.0002). Age was inversely correlated with thyroid
and sex hormone levels (Additional file 2: Table S2).
With the exception of TSH, LMMs showed that thy-
roid hormone levels differed significantly by study visit
(Table 3). We found significantly higher mean levels of
serum FT3 and FT4 at visit 1 compared to corresponding
levels at visit 3. Conversely, the mean serum levels of
all three sex hormones were significantly lower at visit
1 compared to visit 3.
Table 4 shows the fully adjusted longitudinal associa-
tions between urinary phthalate metabolite concentrations
and serum hormones concentrations from LMMs. Each
model contained random intercepts only for subject ID to
account for intra-individual correlation, as addition of
random slopes did not improve the model fit. A likelihood
ratio test for fixed effects indicated that maternal educa-
tion did not have a significant effect on serum hormone
levels. Thus, prepregnancy BMI, maternal age, study
visit, and urinary specific gravity were the only covariates
retained in the final models. The crude regression results
were similar to the adjusted results (not shown). We
detected a significant inverse relationship between MCPP
and FT3, where an IQR increase in MCPP was associated
with a 2.89% decrease in FT3 (95% CI = −5.65 to −0.02,
p = 0.049). We also observed a significant inverse associ-




TSH (uIU/mL)† 195 1.13 (1.62) 0.
Free T3 (pg/mL) 195 3.94 (0.60) 3.
Free T4 (ng/dL) 195 1.39 (0.32) 1.
Sex hormones*
Progesterone (ng/mL)† 193 62.8 (1.60) 45
Estradiol (ng/mL) 189 8.16 (4.06) 4.
SHBG (nmol/L) 157 368 (109) 2
SD, standard deviation, TSH, thyroid-stimulating hormone, SHBG, sex hormone-bind
†Geometric mean and geometric standard deviation reported.
*Limitations in sample volume contributed to differences in available samples for eMEP was associated with a 10.6% decrease in progester-
one (95% CI = −17.6 to −2.84, p = 0.01). We detected no
significant associations between serum hormones levels
and ΣDEHP urinary metabolites in longitudinal analyses.
Similarly, null results were observed for individual DEHP
metabolites, with the exception of a marginally signifi-
cant inverse association found between MEHHP and
SHBG (percent change in outcome with IQR increase
[%Δ] = −4.62, 95% CI = −10.0 to 0.75, p = 0.09). Most
urinary phthalate metabolites were positively associated
with TSH, although none of these relationships were sta-
tistically significant. We also found no statistically signifi-
cant associations for FT4 or estradiol in the longitudinal
analyses.
In our examination of the potential interaction between
study visit and urinary phthalate metabolite concentra-
tions in longitudinal analyses, we observed that study visit
significantly modified the relationships between FT3
and MBzP (p = 0.03) and MCPP (p = 0.03), between
FT4 and MiBP (p = 0.01) and ΣDEHP metabolites (p =
0.048), and between TSH and MBP (p = 0.04). We found
no statistically significant interactions between study visit
and urinary phthalate metabolites for any of the sex hor-
mones examined (data not shown).
Table 5 presents the results from cross-sectional analyses
by study visit for associations between urinary phthalate
metabolites and serum thyroid hormone concentrations.
At visit 1, we observed a statistically significant positive as-
sociation between MiBP and FT4 (%Δ =4.95, 95% CI = 0.27
to 9.28, p = 0.04). MBzP and ΣDEHP metabolites were also
positively, though not significantly, associated with FT4 at
visit 1. At visit 3, urinary phthalate metabolites were gener-
ally inversely associated with FT4. At this visit, we found a
statistically significant inverse association between ΣDEHP
and FT4 (%Δ = −8.02, 95% CI = −15.3 to −0.80, p = 0.03).
Urinary phthalate metabolites were generally positively
associated with TSH at each study visit, and suggestive
associations were observed with MBzP at visit 1 and MEP06 pregnant women)
Selected percentiles
th 50th 75th 95th Max.
81 1.10 1.51 2.83 4.29
50 3.90 4.40 4.90 5.70
20 1.40 1.50 1.90 3.10
.7 57.3 82.0 140 374
79 7.58 11.8 15.0 15.0
93 352 428 563 736
ing globulin.
ach sex hormone.
Table 3 Mean serum hormone concentrations (SD) by







TSH (uIU/mL)† 1.10 (1.60) 1.17 (1.65) 0.25
Free T3 (pg/mL) 4.01 (0.61) 3.86 (0.59) 0.02
Free T4 (ng/dL) 1.45 (0.31) 1.32 (0.32) 0.001
Sex Hormones
Progesterone (ng/mL)† 46.9 (1.37) 88.4 (1.48) <0.001
Estradiol (ng/mL) 5.70 (2.48) 11.1 (3.60) <0.001
SHBG (nmol/L) 349 (108) 391 (106) 0.002
SD, standard deviation, TSH, thyroid-stimulating hormone, SHBG, sex
hormone-binding globulin.
†Geometric mean and geometric standard deviation reported.
*Test for fixed effects from linear mixed models with random intercepts.
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MCPP and MCOP at visit 1, these effects were greater and
statistically significant at visit 3.
The results of cross-sectional analyses for the relationships
between urinary phthalate metabolites and sex hormone
concentrations are presented in Table 6. We observed a
marginally significant inverse relationship between
MEP and SHBG at visit 1 (%Δ = −10.1, 95% CI = −21.8
to 1.65, p = 0.09), and a null association at visit 3. The
inverse association between MEP and progesteroneTable 4 Longitudinal analysis: percent change (95% CIs) in th
interquartile range increase in urinary phthalate metabolite c
Analyte % Change (95% CI) p-value % Change (95%
Free T3 (n = 181 observations) Free T4 (n = 1
MBzP 0.18 (−3.42, 3.77) 0.92 0.58 (−4.45, 5.5
MBP 1.33 (−1.90, 4.67) 0.42 0.63 (−4.00, 5.2
MiBP 0.19 (−2.86, 3.14) 0.90 1.14 (−3.06, 5.4
MEP 1.11 (−2.74, 4.96) 0.57 2.68 (−2.68, 7.8
MCPP −2.89 (−5.65, −0.02) 0.049* −2.01 (−6.12, 2.
MCOP −2.03 (−5.08, 0.98) 0.18 −1.11 (−5.26, 3.
MCNP 0.48 (−2.03, 2.94) 0.71 −1.64 (−5.28, 1.
ΣDEHP −0.28 (−3.63, 0.30) 0.87 −0.93 (−5.56, 3.
Estradiol (n = 175 observations) SHBG (n = 14
MBzP 0.86 (−8.52, 10.3) 0.86 4.89 (−1.52, 11
MBP 2.65 (−5.90, 11.2) 0.54 −0.65 (−6.29, 4.
MiBP 1.56 (−6.27, 9.39) 0.69 1.19 (−4.25, 6.6
MEP 1.60 (−8.49, 11.7) 0.75 −2.24 (−9.43, 4.
MCPP −3.86 (−11.5, 3.80) 0.32 −1.27 (−6.40, 3.
MCOP −3.59 (−11.4, 4.24) 0.36 −0.93 (−6.44, 4.
MCNP −2.03 (−8.50, 4.41) 0.53 −0.66 (−4.85, 3.
ΣDEHP −0.56 (−9.17, 8.06) 0.90 −4.11 (−9.83, 1.
CI, confidence interval, TSH, thyroid-stimulating hormone, SHBG, sex hormone-bind
and are adjusted for age at enrollment, prepregnancy body mass index, as well as u
*P < 0.05.observed in the longitudinal analyses appeared consistent
across study visits.
Discussion
To our knowledge the present study is the first to examine
the relationships between urinary phthalate metabolites
and serum thyroid hormone levels longitudinally across
pregnancy. Few associations were observed in longitudinal
analyses, although we did find statistically significant in-
verse associations between FT3 and MCPP, a non-specific
metabolite of several high molecular weight phthalate
plasticizers, and also between progesterone and MEP, the
main metabolite of diethyl phthalate commonly used in
personal care products. We also found that study visit of
sample collection significantly modified the relationships
between certain urinary phthalate metabolites and thyroid
hormone levels. Our cross-sectional analyses corroborated
our findings from the interaction analyses, and showed
that associations between certain urinary phthalate metab-
olites and FT3 and FT4 hormone levels differed markedly
(in terms of both magnitude and significance) based on
visit of sample collection. For visit 1, associations with
FT3 and FT4 were generally inverse, but at visit 3 these
inverse relationships were stronger. Taken together, these
results suggest that phthalate exposure during pregnancy
may alter maternal thyroid and sex hormone levels.
They also suggest that the magnitude of the potentialyroid and sex hormone concentrations in relation to
oncentration
CI) p-value % Change (95% CI) p-value
81 observations) ln-TSH (n = 181 observations)
6) 0.82 5.51 (−4.40, 16.5) 0.28
1) 0.79 3.28 (−5.58, 12.8) 0.48
2) 0.59 4.64 (−3.73, 13.0) 0.28
3) 0.33 0.05 (−10.1, 11.3) 0.99
10) 0.34 1.60 (−6.05, 9.88) 0.68
13) 0.61 −2.52 (−10.3, 6.13) 0.56
93) 0.36 3.50 (−2.98, 10.4) 0.30
79) 0.70 7.21 (−1.87, 16.6) 0.12
7 observations) ln-progesterone (n = 179 observations)
.3) 0.13 3.16 (−4.56, 11.5) 0.67
98) 0.82 3.71 (−3.44, 11.2) 0.31
1) 0.66 2.48 (−3.96, 9.49) 0.46
97) 0.54 −10.6 (−17.6, −2.84) 0.01*
86) 0.62 −4.31 (−10.2, 1.98) 0.17
58) 0.74 −4.83 (−11.0, 1.57) 0.13
46) 0.75 −2.06 (−7.22, 3.28) 0.43
62) 0.16 1.79 (−5.17, 9.39) 0.62
ing globulin. Linear mixed models include a random intercept for subject ID
rinary specific gravity and study visit.
Table 5 Cross-sectional analysis: percent change (95% CIs) in thyroid hormone concentrations in relation to
interquartile range increase in urinary phthalate metabolite concentration by visit during gestation
Visit 1 (16–20 weeks)
Analyte % Change (95% CI) p-value % Change (95% CI) p-value % Change (95% CI) p-value
Free T3 (n = 100 observations) Free T4 (n = 100 observations) ln-TSH (n = 100 observations)
MBzP 1.87 (−2.55, 6.37) 0.40 2.44 (−2.77, 7.65) 0.36 12.9 (−0.93, 28.2) 0.07†
MBP −0.72 (−4.94, 3.29) 0.73 0.26 (−4.58, 5.04) 0.92 1.29 (−10.2, 13.7) 0.83
MiBP −1.64 (−5.55, 2.42) 0.43 4.95 (0.27, 9.28) 0.04* 1.09 (−10.3, 13.9) 0.86
MEP −0.20 (−5.37, 5.02) 0.94 −0.05 (−6.10, 6.10) 0.99 0.77 (−13.6, 17.7) 0.92
MCPP −1.04 (−4.54, 2.62) 0.57 1.41 (−2.83, 5.80) 0.50 −2.57 (−12.7, 8.69) 0.64
MCOP −0.50 (−4.11, 2.93) 0.78 −0.44 (−4.58, 3.76) 0.83 −0.39 (−10.3, 10.7) 0.94
MCNP 1.05 (−2.27, 4.49) 0.53 0.43 (−3.47, 4.37) 0.83 −2.68 (−11.9, 7.35) 0.58
ΣDEHP −1.62 (−6.05, 2.85) 0.47 3.09 (−2.17, 8.27) 0.25 7.14 (−6.12, 22.3) 0.30
Visit 3 (24–28 weeks)
Free T3 (n = 81 observations) Free T4 (n = 81 observations) ln-TSH (n = 81 observations)
MBzP −2.67 (−8.3, 2.86) 0.34 −2.97 (−12.1, 6.07) 0.51 −4.62 (−20.4, 13.5) 0.58
MBP −0.57 (−5.68, 4.34) 0.82 −1.46 (−9.67, 6.74) 0.72 9.57 (−6.27, 27.3) 0.25
MiBP −2.51 (−6.81, 1.70) 0.24 −4.70 (−11.8, 2.08) 0.17 2.74 (−9.94, 17.9) 0.68
MEP 2.76 (−2.68, 8.44) 0.32 4.93 (−3.81, 13.7) 0.27 18.1 (0.00, 37.8) 0.05†
MCPP −5.93 (−10.2, −1.75) 0.01* −5.11 (−12.5, 2.22) 0.17 2.41 (−11.1, 17.7) 0.74
MCOP −5.83 (−10.8, −0.58) 0.03* −3.02 (−11.5, 5.38) 0.47 −3.35 (−17.1, 13.6) 0.67
MCNP −1.44 (−5.92, 3.10) 0.54 −6.34 (−14.0, 0.99) 0.09† 5.39 (−8.50, 21.3) 0.46
ΣDEHP 0.05 (−4.49, 4.49) 0.98 −8.02 (−15.3, −0.80) 0.03* 2.79 (−10.8, 18.6) 0.70
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http://www.rbej.com/content/13/1/4endocrine-disrupting effect of phthalates may depend
on the timing of exposure during gestation.
Of the thyroid hormones, we observed that FT4 was
inversely associated with certain urinary phthalate metab-
olites at visit 3 (26 ± 2 weeks of gestation). These results
are in contrast to a previous cross-sectional investigation
conducted among 76 Taiwanese pregnant women with
urinary phthalate metabolites and hormone levels mea-
sured in the second trimester (mean time of sample
collection = 27.9 ± 2.3 weeks of gestation) [23]. Huang
and colleagues reported a statistically significant inverse
association between urinary MBP and serum FT4 after
adjusting for similar covariates in their regression model.
We did not observe an analogous association at visit 3
(a comparable gestational age at sample collection) in
the present study. FT3 was not measured in this previ-
ous investigation and regression results for TSH were
not presented by the authors, thereby precluding additional
comparisons with findings from our analyses. Differences
between the results of our study and the Taiwanese study
may be due to dissimilarities in study design, participant
demographic characteristics, exclusion/inclusion criteria
and/or exposures. For example, the median concentration
(unadjusted for urinary dilution) of MBP was approximatelyfour times higher in the Taiwanese pregnant women
(81.8 ng/mL) [23] compared to the corresponding con-
centration found in women in the PROTECT cohort
(20.1 ng/mL) [31].
Our findings for urinary metabolites of DEHP and serum
FT4 and TSH are consistent with a previous study of
adults (including non-pregnant women and men) par-
ticipating in NHANES that reported significant inverse
associations between certain urinary DEHP metabolites
and FT4, although that larger study also reported posi-
tive relationships between these metabolites and TSH
which were not significant in the present study [15].
Our results for FT3 and FT4 are also in agreement with
the limited animal studies in which rats fed DEHP-
contaminated diets, at doses orders of magnitude higher
than those experienced by the PROTECT participants,
had lower plasma T4 levels compared to controls and
plasma T3 levels remained unchanged [42-45].
Various biological mechanisms have been proposed
through which environmental chemicals may exert their
action on thyroid function. Thyroid-disrupting chemicals
may target the hypothalamic-pituitary-thyroid axis at mul-
tiple levels and may disrupt thyroid hormone homeostasis
by interfering with the synthesis and regulation by the
Table 6 Cross-sectional analysis: percent change (95% CIs) in sex hormone concentrations in relation to interquartile
range increase in urinary phthalate metabolite concentration by visit during gestation
Visit 1 (16–20 weeks)
Analyte % Change (95% CI) p-value % Change (95% CI) p-value % Change (95% CI) p-value
Estradiol (n = 97 observations) SHBG (n = 83 observations) ln-progesterone (n = 98 observations)
MBzP −5.65 (−18.9, 7.57) 0.40 4.99 (−4.43, 14.4) 0.29 1.88 (−6.60, 11.3) 0.66
MBP 0.20 (−10.3, 14.2) 0.75 4.13 (−3.66, 11.9) 0.29 5.68 (−2.41, 13.7) 0.18
MiBP −0.99 (−13.1, 11.1) 0.87 −0.92 (−9.77, 7.28) 0.77 5.56 (−2.46, 13.9) 0.18
MEP 0.03 (−15.5, 15.6) 1.00 −10.1 (−21.8, 1.65) 0.09† −12.15 (−20.5, −2.99) 0.01*
MCPP −2.93 (−14.4, 8.54) 0.61 −2.66 (−10.6, 5.27) 0.51 −0.42 (−7.61, 7.34) 0.91
MCOP 0.70 (−9.86, 11.3) 0.90 0.86 (−6.74, 8.48) 0.82 −0.57 (−7.27, 6.62) 0.87
MCNP 2.43 (−7.42, 12.3) 0.63 −0.65 (−7.75, 6.45) 0.86 −0.58 (−6.85, 6.11) 0.86
ΣDEHP −7.50 (−20.9, 5.92) 0.27 −5.93 (−15.4, 3.54) 0.22 2.37 (−6.23, 11.9) 0.59
Visit 3 (24–28 weeks)
Estradiol (n = 78 observations) SHBG (n = 64 observations) ln-progesterone (n = 81 observations)
MBzP 4.38 (−7.12, 15.9) 0.45 6.66 (−4.98, 18.3) 0.26 8.02 (−5.12, 23.4) 0.24
MBP 6.55 (−3.60, 16.7) 0.20 5.22 (−5.18, 15.7) 0.32 8.19 (−3.61, 21.0) 0.18
MiBP 2.42 (−5.96, 10.8) 0.57 3.46 (−4.89, 11.8) 0.41 2.86 (−6.81, 13.8) 0.58
MEP 1.36 (−9.57, 12.3) 0.81 1.00 (−10.4, 12.4) 0.86 −9.43 (−20.1, 2.51) 0.11
MCPP −0.48 (−9.45, 8.48) 0.91 4.76 (−3.69, 13.2) 0.26 −3.81 (−11.8, 6.87) 0.47
MCOP −2.17 (−12.4, 8.09) 0.67 3.93 (−5.77, 13.6) 0.42 −5.15 (−15.7, 7.06) 0.39
MCNP −2.64 (−11.7, 6.45) 0.57 2.70 (−6.31, 11.7) 0.55 −3.99 (−13.9, 6.75) 0.45
ΣDEHP 2.87 (−6.17, 11.9) 0.53 1.14 (−8.61, 10.9) 0.82 5.85 (−4.81, 17.6) 0.29
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http://www.rbej.com/content/13/1/4hypothalamic-pituitary thyroid hormones (i.e., thyrotropin-
releasing hormone [TRH] and TSH), binding of thyroid
hormones to distributor proteins, cellular uptake mech-
anisms of thyroid hormones, metabolism of thyroid
hormones by iodothyronine deiodinases, transcriptional
activity of thyroid hormone receptors and/or receptor
activation [46,47]. It has been suggested that phthalates
may bind to thyroid hormone receptors, consequently
activating or inhibiting thyroid hormone action [48-50],
although data overtly demonstrating the binding of phtha-
lates to thyroid receptors are lacking. Available experi-
mental studies have provided some evidence for these
potential mechanisms of thyroid disruption. In vitro stud-
ies have shown that phthalates may alter the sodium/
iodide symporter-mediated uptake of iodide by thyroid
follicular cells [51,52], exhibit thyroid receptor antagon-
ist activities [24,53,54], or displace thyroid hormones
(e.g., T3) from distributor proteins [55]. Additionally,
phthalates were found to alter the transcription of genes
involved in the hypothalamic-pituitary-thyroid axis as
well as the whole-body content of thyroid hormones in
zebrafish [56].
Of the sex hormones, we observed a consistent inverse
relationship between urinary MEP and serum progesteroneacross the two time points in pregnancy. In contrast to
these findings, the previously described study by Huang
et al. [23] reported no relationship between urinary
MEP or other phthalate metabolites and progesterone
during approximately the same sampling period in
pregnancy as visit 3 in the current study. At visit 1 (18 ±
2 weeks of gestation), we observed a marginally significant
inverse relationship between urinary MEP and SHBG,
although no association was observed at visit 3. These
results are in agreement with a previous study conducted
among 1,377 pregnant Australian women, in which an in-
verse relationship between serum MEP and SHBG con-
centrations was observed early in pregnancy (18 weeks of
gestation) [30]. Animal studies investigating the potential
toxicity of phthalates on the female reproductive system
are scarce, and have primarily examined effects of DEHP
and DBP. These phthalates have been shown to reduce
progesterone production in female rats in vivo and in rat
granulosa cells in vitro [57-59]. However, we did not
observe these relationships with metabolites of DEHP
and DBP in the present analysis.
Our null findings for estradiol were comparable to those
of previous epidemiologic studies conducted among preg-
nant women [23,29]. However, available toxicological data
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of preovulatory follicles, may be the primary target site for
DEHP [60]. Specifically, in vivo and in vitro studies of
DEHP-treated female cycling rats have demonstrated that
suppressed estradiol production may be the principal
functional modification by DEHP [60-62]. These toxicol-
ogy studies suggest that phthalates have the potential to
induce alterations in steroidogenesis in female animals,
although further research is needed to fully characterize
the specific modes of action. Examining this association
in a larger sample of pregnant women may enable iden-
tification of subtler relationships.
While the timing of exposure to endocrine disrupting
chemicals during pregnancy has been shown to influence
both the severity and onset of adverse developmental and
reproductive outcomes [63], we are aware of no epidemio-
logic studies that have attempted to identify periods of
susceptibility to phthalate-induced alterations in thyroid
and sex steroid hormone levels in pregnant women.
During the first trimester, the fetus relies solely on ma-
ternal T3 and T4 until the fetal thyroid gland fully de-
velops at approximately 10 weeks of gestation [64]. Thus,
maintaining maternal euthyroidism during the first tri-
mester is critical – even slight alterations in maternal thy-
roid hormones during this period of gestation has been
associated with deleterious neurodevelopmental and re-
productive outcomes [65-67]. In later pregnancy, maternal
thyroid hormones are essential for fetal thyroid homeo-
stasis [68]. Although we detected a significant inverse
relationship between urinary MiBP and serum FT4 in
the first trimester (i.e., at visit 1), the strongest findings
for FT4 were observed in the second half of pregnancy
(i.e., at visit 3). Despite epidemiological investigations
that have shown the potential adverse reproductive conse-
quences of overt thyroid disease in early and late gestation
[69,70], the impact of trimester-specific subclinical alter-
ations in maternal thyroid function on pregnancy outcomes
remains largely understudied. Furthermore, we observed a
consistent inverse association between urinary MEP and
progesterone at each study visit, and this effect was greatest
earlier in pregnancy (i.e., visit 1). Because progesterone
plays an essential physiological role in the establishment
and maintenance of pregnancy, insufficient concentrations
of this hormone throughout gestation may lead to preg-
nancy loss or preterm birth, depending on the timing of
hormonal disruption [12,71,72].
While our findings may have important public health
implications, our study has several limitations. Character-
istic of most preliminary analyses in an ongoing prospect-
ive cohort, our study was limited by a small sample
size. We expected that the availability of multiple mea-
surements per subject would increase the power to de-
tect associations, but analysis revealed that the effects
of phthalates on hormone disruption may be differentdepending on timing of exposure. Furthermore, given
the large number of statistical tests performed in the
present analyses, there is possibility of type-1 error. An-
other potential limitation is our timing of data collection
during mid-pregnancy, which may potentially bias our re-
sults since women who spontaneously aborted in the first
trimester are not captured in our analyses. We do not
have biological data from these women pertaining to the
exposure and outcomes of interest to assess the direction
of the potential bias. Our study may also have been limited
by our evaluation of circulating thyroid hormones as a
sole indicator of thyroid toxicity [73]. Measurements of
peripheral thyroid hormones may not fully capture the
phthalate-induced effects on thyroid homeostasis [68].
That is, blood levels of thyroid hormones may not cor-
respond with actions at the receptor, such as regulation
of gene expression and the developmental processes in
which they are involved [73,74]. However, given the
limited amount of data on this subject and the infeasi-
bility of collecting more specific markers during pregnancy,
levels of circulating thyroid hormone measurements may
serve as the most appropriate biomarker of thyroid dis-
ruption in pregnant women. Additional studies are ne-
cessary to address potential phthalate-induced alterations
in thyroid-hormone responsive genes relevant to pregnancy
outcomes. It may also be possible that the serum mea-
surements included in our analyses represented transi-
ent changes in thyroid and sex hormone levels that may
not have persisted outside of the two measurement time
points. However, even temporary and/or subclinical alter-
ations in maternal hormone levels may be biologically
relevant and may induce permanent effects on parturition
and/or the developing fetus [68]. Our study was also lim-
ited by the lack of information concerning the iodine and
selenium status of our study participants, which may be
important because deficiencies in these trace elements can
impair normal thyroid hormone function [75]. However,
we have no reason to expect that these would be associ-
ated with phthalate exposure, so any deficiencies in
these substances would affect the precision of the effect
estimates rather than the effect estimates themselves [76].
Finally, our study was conducted among pregnant women
in Northern Puerto Rico, which may have implications for
the generalizability of results.
Despite these limitations, our study had several strengths.
The collection of biomarker measurements at two time
points during pregnancy enabled us to utilize mixed
modeling techniques to more powerfully detect associa-
tions among repeated measurements and also evaluate
potential periods of gestation during which phthalates
may have a more profound impact on maternal hormone
levels. Also, as pregnancy is characterized by a dynamic
interplay between maternal endocrine hormones, our
measurements of hormone concentrations from two
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http://www.rbej.com/content/13/1/4disparate endocrine axes is advantageous. Each set of
hormones may represent distinct mechanisms through
which phthalates may influence downstream reproductive
health outcomes. Furthermore, we used novel and precise
analytical techniques to measure serum levels of FT3 and
FT4. Especially pertinent to a population of pregnant
women, this method has advantages over traditional
immunoassays because it is more specific, does not cross-
react with other analytes, and is not influenced by serum
binding proteins [35,77,78]. Notably, thyroxine binding
proteins may increase as much as 50 percent during preg-
nancy [78].
Conclusions
The results of our study provide suggestive evidence for
phthalate-induced endocrinal disturbances during preg-
nancy, and may augment mechanistic understanding of
the impact of phthalates on reproductive health outcomes.
Future research on the specific pathways through which
phthalates may alter thyroid and sex hormone concen-
trations are required for targeted interventions aimed
at preventing downstream hormone-mediated adverse
reproductive health outcomes in pregnant women.
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